THE WHAT? Scheduling and funds software program supplier Boulevard has raised US$80 million in Sequence D funding, bringing its valuation to almost US$800 million as demand surges for medspa companies together with Botox and GLP-1-based weight reduction remedies.
THE DETAILS Based in 2016 to streamline salon bookings, Boulevard has expanded its software program providing throughout magnificence and wellness sectors, with current development pushed by the rise of medical aesthetic clinics. The corporate experiences that medspas—providing companies resembling fillers, laser remedies, and weight administration prescriptions—now make up a good portion of its shopper base.
The software program, initially constructed for salons, was tailored to fulfill medspa necessities, together with HIPAA compliance and options like injection mapping. Boulevard now claims to serve round 15% of U.S. medspas. The newest funding spherical was led by JMI Fairness, with participation from current traders Index Ventures and VMG Companions. Boulevard estimates it’s going to course of US$5 billion in funds this 12 months, after introducing fee seize to scale back no-show charges.
THE WHY? The funding displays a wider shift within the magnificence sector as conventional salon companies converge with medical aesthetics. Demand for Botox, fillers, and GLP-1 medication has created a brand new operational mannequin for magnificence companies—one which sits exterior conventional healthcare and insurance coverage billing techniques. Software program platforms like Boulevard are positioning themselves as infrastructure suppliers for this fast-evolving house.
Supply: Tech Crunch
